Vancomycin Dosing in Critically Ill Patients: Robust Methods for Improved Continuous-Infusion Regimens

ABSTRACT Despite the development of novel antibiotics active against Gram-positive bacteria, vancomycin generally remains the first treatment, although rapidly achieving concentrations associated with maximal efficacy provides an unresolved challenge. The objective of this study was to conduct a population pharmacokinetic analysis of vancomycin in a large population of critically ill patients. This was a retrospective data collection of 206 adult septic critically ill patients who were administered vancomycin as a loading dose followed by continuous infusion. The concentration-versus-time data for vancomycin in serum was analyzed by a nonlinear mixed-effects modeling approach using NONMEM. Monte Carlo simulations were performed using the final covariate model. We found that the best population pharmacokinetic model consisted of a one-compartment linear model with combined proportional and additive residual unknown variability. The volume of distribution of vancomycin (1.5 liters/kg) was described by total body weight and clearance (4.6 liters/h) by 24-hour urinary creatinine clearance (CrCl), normalized to body surface area. Simulation data showed that a 35-mg/kg loading dose was necessary to rapidly achieve vancomycin concentrations of 20 mg/liter. Daily vancomycin requirements were dependent on CrCl, such that a patient with a CrCl of 100 ml/min/1.73 m2 would require at least 35 mg/kg per day by continuous infusion to maintain target concentrations. In conclusion, we have found that higher-than-recommended loading and daily doses of vancomycin seem to be necessary to rapidly achieve therapeutic serum concentrations in these patients.

[1]  Jerome J. Schentag,et al.  Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections , 2004, Clinical pharmacokinetics.

[2]  Joshua A. Doherty,et al.  Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. , 2006, Chest.

[3]  J. Roberts,et al.  Pharmacokinetic issues for antibiotics in the critically ill patient , 2009, Critical care medicine.

[4]  M. Rybak,et al.  The pharmacokinetic and pharmacodynamic properties of vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  K. Ho,et al.  Risk Factors and Outcomes of Methicillin-resistant Staphylococcus Aureus Bacteraemia in Critically Ill Patients: A Case Control Study , 2009, Anaesthesia and intensive care.

[6]  K. Haase,et al.  Use of vancomycin pharmacokinetic–pharmacodynamic properties in the treatment of MRSA infections , 2010, Expert review of anti-infective therapy.

[7]  N H Holford,et al.  A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. , 1999, Computer methods and programs in biomedicine.

[8]  F. Pea,et al.  High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. , 2000, The Journal of antimicrobial chemotherapy.

[9]  G Sherman,et al.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.

[10]  M. Cooper,et al.  Methicillin-resistant Staphylococcus aureus in the critically ill. , 2004, British journal of anaesthesia.

[11]  D. Levine,et al.  Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  P. Viale,et al.  Prospectively Validated Dosing Nomograms for Maximizing the Pharmacodynamics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients , 2009, Antimicrobial Agents and Chemotherapy.

[13]  T. Similowski,et al.  Continuous versus Intermittent Infusion of Vancomycin in Severe Staphylococcal Infections: Prospective Multicenter Randomized Study , 2001, Antimicrobial Agents and Chemotherapy.

[14]  A. Jeurissen,et al.  A higher dose of vancomycin in continuous infusion is needed in critically ill patients. , 2011, International journal of antimicrobial agents.

[15]  P. Marik Aminoglycoside Volume of Distribution and Illness Severity in Critically Ill Septic Patients , 1993, Anaesthesia and intensive care.

[16]  J. Garnacho-Montero,et al.  Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis* , 2003, Critical care medicine.

[17]  J. Bédos,et al.  Methicillin-resistant Staphylococcus aureus pneumonia treatment: do not confuse pharmacokinetics and pharmacodynamics. , 2007, Chest.

[18]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[19]  N. Holford,et al.  Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. , 2004, British journal of clinical pharmacology.

[20]  J. Jernigan,et al.  Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. , 2009, JAMA.

[21]  A. Sánchez Navarro,et al.  Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients , 2007, Intensive Care Medicine.

[22]  J. Vincent,et al.  Comparison of dopamine and norepinephrine in the treatment of shock. , 2010, The New England journal of medicine.

[23]  R. Bellomo,et al.  Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units , 2004, Intensive Care Medicine.

[24]  N. V. Jiménez-Torres,et al.  Population pharmacokinetic parameters of vancomycin in critically ill patients , 2006, Journal of clinical pharmacy and therapeutics.

[25]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[26]  F. Colardyn,et al.  Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. , 2002, Archives of internal medicine.

[27]  理 福田,et al.  University of California, San Francisco , 1974, Medical History.

[28]  George L. Drusano,et al.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.

[29]  L. Bauer,et al.  Vancomycin dosing in morbidly obese patients , 1998, European Journal of Clinical Pharmacology.

[30]  D. Alexander,et al.  Optimizing Vancomycin Dosing through Pharmacodynamic Assessment Targeting Area under the Concentration-Time Curve/Minimum Inhibitory Concentration , 2009 .

[31]  K. Wood,et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.

[32]  C. Sprung,et al.  Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. , 1998, Critical care medicine.